Enteric Diseases Group, MCRI.
Enteric Diseases Group, MCRI and the Australian Rotavirus Surveillance Group Enteric Diseases Group, Murdoch Children's Research Institute, Royal Children's Hospital.
Commun Dis Intell (2018). 2021 Jan 29;45. doi: 10.33321/cdi.2021.45.6.
This report, from the Australian Rotavirus Surveillance Program and collaborating laboratories Australia-wide, describes the rotavirus genotypes identified in children and adults with acute gastroenteritis during the period 1 January to 31 December 2018. During this period, 690 faecal specimens were referred for rotavirus G- and P- genotype analysis, including 607 samples that were confirmed as rotavirus positive. Of these, 457/607 were wild-type rotavirus strains and 150/607 were identified as rotavirus vaccine-like. Genotype analysis of the 457 wild-type rotavirus samples from both children and adults demonstrated that G3P[8] was the dominant genotype nationally, identified in 52% of samples, followed by G2P[4] (17%). The Australian National Immunisation Program, which previously included both RotaTeq and Rotarix vaccines, changed to Rotarix exclusively on 1 July 2017. Continuous surveillance is needed to identify if the change in vaccination schedule could affect rotavirus genotype distribution and diversity in Australia.
本报告来自澳大利亚轮状病毒监测计划和全澳合作实验室，描述了 2018 年 1 月 1 日至 12 月 31 日期间患有急性肠胃炎的儿童和成人中鉴定出的轮状病毒基因型。在此期间，有 690 份粪便标本被转介进行轮状病毒 G 和 P 基因型分析，其中 607 份被确认为轮状病毒阳性。在这 607 份阳性样本中，457 份为野生型轮状病毒株，150 份为轮状病毒疫苗样。对来自儿童和成人的 457 份野生型轮状病毒样本的基因型分析表明，G3P[8]是全国范围内的主要基因型，占样本的 52%，其次是 G2P[4]（17%）。澳大利亚国家免疫计划之前包括 RotaTeq 和 Rotarix 疫苗，于 2017 年 7 月 1 日改为仅使用 Rotarix。需要持续监测以确定接种时间表的变化是否会影响澳大利亚轮状病毒基因型的分布和多样性。
